{
    "clinical_study": {
        "@rank": "21529", 
        "arm_group": {
            "arm_group_label": "Ipilimumab + Dacarbazine", 
            "arm_group_type": "Experimental", 
            "description": "Ipilimumab 10 mg/kg injection and Dacarbazine 850 mg/m2 injection by Intravenous.\nIpilimumab: Every 3 weeks up to 4 doses on Induction Phase (24 weeks), and every 12 weeks on Maintenance Phase until PD or intolerable toxicity\nDacarbazine: Every 3 weeks up to 8 doses on Induction Phase (24 Weeks)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine survival rate at 1 year of Ipilimumab plus\n      Dacarbazine (DTIC) in patients with previously untreated Stage III with N3 (unresectable) or\n      Stage IV melanoma"
        }, 
        "brief_title": "Phase 2 Study of Ipilimumab Plus DTIC in Japanese Advanced Melanoma Patients", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Histologic diagnosis of malignant melanoma\n\n          -  Previously untreated Stage III with N3 (unresectable) or Stage IV melanoma\n\n          -  Life expectancy of at least 16 weeks in this study\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n        Exclusion Criteria:\n\n          -  Evidence of brain metastases on brain imaging\n\n          -  Primary ocular or mucosal melanoma\n\n          -  History of or current active autoimmune disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681212", 
            "org_study_id": "CA184-202"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ipilimumab + Dacarbazine", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Biological", 
                "other_name": "BMS-734016"
            }, 
            {
                "arm_group_label": "Ipilimumab + Dacarbazine", 
                "intervention_name": "Dacarbazine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dacarbazine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "8128582"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto-shi", 
                        "country": "Japan", 
                        "state": "Kumamoto", 
                        "zip": "8608556"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsumoto-shi", 
                        "country": "Japan", 
                        "state": "Nagano", 
                        "zip": "3908621"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sunto-gun", 
                        "country": "Japan", 
                        "state": "Shizuoka", 
                        "zip": "4118777"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "1040045"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-shi", 
                        "country": "Japan", 
                        "state": "Yamanashi", 
                        "zip": "4093898"
                    }, 
                    "name": "Local Institution"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Previously Untreated Unresectable or Metastatic Melanoma", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Survival rate defined as the proportion of subjects who are alive after at least one year of follow up following the first dose of study therapy", 
            "safety_issue": "No", 
            "time_frame": "At 1 year after start of study drugs treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681212"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "irAEs will be measured every 3 weeks in induction phase, every 6 weeks in maintenance to Week 48, and every 12 weeks to Progressive Disease (PD)", 
            "measure": "Frequency of Grade 3-4 Immune-related Adverse Events (irAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 90 days following the last dose of Ipilimumab"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}